Spots Global Cancer Trial Database for y90
Every month we try and update this database with for y90 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Prospective Post Y90 Liver Hypertrophy | NCT02783261 | Hepatocellular ... Liver Hypertrop... | CT volumetric m... | 21 Years - 99 Years | Singapore General Hospital | |
| Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable HCC and mCRC | NCT04926376 | Hepatocellular ... Metastatic Colo... Liver Cancer | Eye90 Microsphe... | 18 Years - 99 Years | ABK Biomedical | |
| Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) | NCT05953337 | Hepatocellular ... Hepatocellular ... Liver Cancer | EYE90 Microsphe... | 18 Years - 99 Years | ABK Biomedical | |
| First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device | NCT06192758 | Prostate Cancer | TheraSphere PCa | 50 Years - | Boston Scientific Corporation | |
| First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device | NCT06192758 | Prostate Cancer | TheraSphere PCa | 50 Years - | Boston Scientific Corporation | |
| Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere® | NCT03203837 | Hepatocellular ... | Plasma collecti... | 18 Years - | Northwestern University | |
| A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE | NCT06040099 | Hepatocellular ... | Durvalumab Bevacizumab Transarterial R... | 18 Years - 130 Years | AstraZeneca | |
| Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) | NCT05953337 | Hepatocellular ... Hepatocellular ... Liver Cancer | EYE90 Microsphe... | 18 Years - 99 Years | ABK Biomedical | |
| A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE | NCT06040099 | Hepatocellular ... | Durvalumab Bevacizumab Transarterial R... | 18 Years - 130 Years | AstraZeneca | |
| Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere® | NCT03203837 | Hepatocellular ... | Plasma collecti... | 18 Years - | Northwestern University | |
| Prospective Post Y90 Liver Hypertrophy | NCT02783261 | Hepatocellular ... Liver Hypertrop... | CT volumetric m... | 21 Years - 99 Years | Singapore General Hospital | |
| Yttrium-90 (TARE-Y90) in Children, Adolescents, and Young Adults With Liver Tumors | NCT04315883 | Hepatoblastoma Hepatocellular ... Rhabdoid Tumor ... Undifferentiate... Pediatric Liver... Liver Tumors | Quality of Life... Transarterial R... | 0 Years - 21 Years | Nemours Children's Clinic |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
